Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Foot Ulcer, Diabetic, Infection
Interventions: Gentamicin collagen sponge, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 86
States / cities: Anniston, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more

Conditions: Pancreatic Disease
Interventions: ChiRhoStim, Placebo; Drug
Lead sponsor: ChiRhoClin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Systemic Lupus Erythematosus
Interventions: BI 3000202, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 30
States / cities: Beverly Hills, California • La Palma, California • San Diego, California + 27 more

Conditions: Major Depressive Disorder
Interventions: SR58611A; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Parkinson's Disease (PD)
Interventions: Terazosin 5 MG, Placebo; Drug
Lead sponsor: Ergun Y. Uc; Other
Eligibility: 50 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2031
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy, Elderly
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Progressive Supranuclear Palsy (PSP)
Interventions: ABBV-8E12, Placebo solution for IV infusion on Day 15; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more

Conditions: Sleep, THC, Marijuana, Cannabis
Interventions: Dronabinol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Osteoarthritis, Knee
Interventions: High-dose/short-duration Fisetin, Low-dose/sustained-duration Fisetin, Oral placebo capsule; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 35 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Diabetes
Interventions: Aliskiren, Placebo; Drug · Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Heart Failure
Interventions: LVAD Implant, Aspirin 100mg, Placebo oral tablet; Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 31 more

Conditions: Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
Interventions: Panzyga IVIG, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Glenview, Illinois

Conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions: TAK-906 Maleate, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 17,183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 303
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Anaheim, California • Los Angeles, California • Panama City, Florida + 8 more

Conditions: Depression, Psychosis, Anhedonia
Interventions: Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Vestibular Disorder, Headache, Traumatic Brain Injury
Interventions: Osteopathic Manipulative Treatment; Other
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mason, Michigan

Conditions: Chronic Spontaneous Urticaria
Interventions: Nucala; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Cocaine Dependence
Interventions: vigabatrin, placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • San Francisco, California • Torrance, California + 8 more

Conditions: Schizophrenia
Interventions: BI 409306, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 32
States / cities: Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more

Conditions: Hyperlipidemia
Interventions: ARI-3037MO; Drug
Lead sponsor: Arisaph Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Chino, California • Fort Lauderdale, Florida • Jacksonvile, Florida + 12 more

Conditions: Friedreich's Ataxia
Interventions: GV101, Placebo; Drug
Lead sponsor: Graviton Bioscience Corporation; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Eatontown, New Jersey

Search by objective public record fields.

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder

Terazosin And Metabolic Energetics in Parkinson's Disease

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

Tetrahydrocannabinol (THC) and Sleep

Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

The Effect of Renin Inhibition on Nerve Function in Diabetes

The ARIES HeartMate 3 Pump IDE Study

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease

Safety and Efficacy of Multiple Doses of Canakinumab (ACZ885) in Chronic Obstructive Pulmonary Disease (COPD) Patients

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury

Mepolizumab for the Treatment of Chronic Spontaneous Urticaria

Vigabatrin for Treatment of Cocaine Dependence

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia

GV101 for Friedreich's Ataxia (FA) Treatment